Clinical Trials Logo

Filter by:
NCT ID: NCT02472964 Completed - Breast Cancer Clinical Trials

Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

HERiTAge
Start date: July 2012
Phase: Phase 3
Study type: Interventional

A multicenter, double-blind, randomized, parallel-group, Phase III study of the efficacy and safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus Herceptin® plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer.

NCT ID: NCT02471144 Completed - Clinical trials for Chronic Severe Plaque-type Psoriasis

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Start date: September 29, 2015
Phase: Phase 3
Study type: Interventional

This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to <18 years were enrolled, of which at least 30 were 6 years to <12 years old. Subjects were enrolled at approximately 70 study sites worldwide.

NCT ID: NCT02470884 Completed - Clinical trials for Coronary Artery Disease

FAST Feasibility Study

Start date: June 15, 2015
Phase: N/A
Study type: Interventional

A prospective multi-center, single arm feasibility study to assess the safety and performance of the Boston Scientific Fully Absorbable Scaffold.

NCT ID: NCT02462928 Completed - Clinical trials for Macular Degeneration

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

CEDAR
Start date: June 25, 2015
Phase: Phase 3
Study type: Interventional

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

NCT ID: NCT02447302 Completed - Ulcerative Colitis Clinical Trials

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Start date: October 15, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.

NCT ID: NCT02435992 Completed - Ulcerative Colitis Clinical Trials

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Start date: June 17, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).

NCT ID: NCT02432846 Completed - Clinical trials for Renal Cell Carcinoma, Metastatic

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

MERECA
Start date: April 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib post-nephrectomy vs Sunitinib post-nephrectomy patients.

NCT ID: NCT02425891 Completed - Clinical trials for Triple Negative Breast Cancer

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Start date: June 23, 2015
Phase: Phase 3
Study type: Interventional

This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.

NCT ID: NCT02425644 Completed - Multiple Sclerosis Clinical Trials

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

OPTIMUM
Start date: June 4, 2015
Phase: Phase 3
Study type: Interventional

International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis

NCT ID: NCT02413580 Completed - Clinical trials for Myasthenia Gravis Exacerbations

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Start date: March 2015
Phase: Phase 3
Study type: Interventional

This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.